1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,500 | 10,600 | 17.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.06. | Agomab gibt Design für Phase-2b-Studie zu Morbus-Crohn-Medikament bekannt | 4 | Investing.com Deutsch | ||
| 23.06. | Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib | 1 | Benzinga.com | ||
| 23.06. | Agomab announces Phase 2b study design for Crohn's disease drug | 1 | Investing.com | ||
| 23.06. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.06. | AgomAb Therapeutics NV: Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease | 471 | GlobeNewswire (Europe) | -- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation... ► Artikel lesen | |
| 22.06. | H.C. Wainwright initiates Agomab stock coverage with buy rating | 1 | Investing.com | ||
| 27.05. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| AGOMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.05. | AgomAb Therapeutics NV: Agomab Announces Results of Annual General Meeting | 163 | GlobeNewswire (Europe) | Antwerp, Belgium, May 27, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual... ► Artikel lesen | |
| 24.04. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.04. | AgomAb Therapeutics NV: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook | 268 | GlobeNewswire (Europe) | -- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --... ► Artikel lesen | |
| 23.04. | Agomab Therapeutics NV - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 26.03. | Agomab receives U.S. patent for lung fibrosis drug candidate | 3 | Investing.com | ||
| 26.03. | AgomAb Therapeutics N.V.: Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis | 162 | GlobeNewswire (Europe) | Antwerp, Belgium, March 26, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent... ► Artikel lesen | |
| 11.03. | Agomab Therapeutics NV - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.03. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.03. | Morgan Stanley initiates Agomab Therapeutics stock with overweight rating | 5 | Investing.com | ||
| 03.03. | Morgan Stanley stuft Agomab Therapeutics mit "Overweight" ein und sieht 73 % Kurspotenzial | 2 | Investing.com Deutsch | ||
| 03.03. | JPMorgan initiates Agomab Therapeutics stock at Overweight | 2 | Investing.com | ||
| 03.03. | JPMorgan startet Coverage für Agomab Therapeutics mit "Overweight" | 2 | Investing.com Deutsch | ||
| 09.02. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 3 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,450 | +3,38 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,217 | +3,83 % | Bayer und Novo Nordisk feiern Comeback! BioNxt Solutions Aktie als Nächstes? | Mit seiner GLP-1-Therapie in Tablettenform hat Novo Nordisk an der Börse wieder in die Erfolgsspur zurückgefunden. Seit April ist die Aktie des dänischen Pharmakonzerns um fast 50 % auf rund 43 EUR... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,044 | +1,06 % | BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer | PARIS (dpa-AFX) - BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect.In... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,180 | +0,72 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 63,88 | +2,40 % | This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | ||
| ATAIBECKLEY | 6,300 | +0,80 % | Dicke Hot-Stock-Überraschung: All for one Group und AtaiBeckley feiern Aktien-Deals - 400 ... | Der CEO von All for One sagte mir noch im Mai im AKTIONÄR TV, er sei "sehr glücklich" mit seinen Aktien - nun die Kursverdopplung. Auch das Spezial-Pharma-Start-up AtaiBeckley feiert ein Happy End -... ► Artikel lesen | |
| ALDEYRA | 1,470 | -2,00 % | Aldeyra Therapeutics, Inc. - 8-K, Current Report | ||
| ABCELLERA BIOLOGICS | 5,680 | +5,19 % | AbCellera-Aktie - Chance nach der Korrektur? | Die AbCellera-Aktie steht nach ihrer kräftigen Korrektur erneut im Fokus der Anleger. Nach dem deutlichen Rücksetzer stellt sich nun die Frage, ob sich auf dem aktuellen Kursniveau eine attraktive Einstiegsgelegenheit... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 19,750 | +2,17 % | CSE Bulletin: Consolidation - Adaptogenics Health Corp. (ADPT) | Le 13 juillet/July 2026
Adaptogenics Health Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated share for four (4) pre-consolidated... ► Artikel lesen | |
| BIOMERIEUX | 73,05 | +1,32 % | Dividendenbekanntmachungen (09.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMEREN CORPORATION US0236081024 0,75 USD 0,6501 EUR AMUNDI SA FR0004125920 - 4,25 EUR BECTON DICKINSON AND COMPANY US0758871091 1... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,530 | -3,03 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| AC IMMUNE | 1,898 | -0,63 % | AC Immune SA: AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease | AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three... ► Artikel lesen | |
| 10X GENOMICS | 37,850 | -2,70 % | 10x Genomics, Inc.: 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group | Acquisition Expands 10x Genomics' Capabilities in Proteomics
PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science... ► Artikel lesen | |
| AGIOS | 33,400 | -1,76 % | Agios Pharmaceuticals, Inc.: U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease | FDA's PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,776 | +1,84 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen |
AGOMAB THERAPEUTICS NV ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,70 % bei einem Aktienkurs von 11,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AGOMAB THERAPEUTICS NV ADR finden Sie auf Wallstreet Online.